Cost-effectiveness of Tumor Treating Fields in Advanced Pancreatic Cancer Evaluated
The PANOVA-3 trial shows that Tumor Treating Fields combined with gemcitabine and nab-paclitaxel improves overall survival and progression-free survival in locally advanced pancreatic cancer patients.
Phase III
Oncology / Pancreatic Cancer
Status
Active
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The PANOVA-3 trial results indicate that Tumor Treating Fields could significantly improve treatment outcomes for patients with locally advanced pancreatic cancer, a group with limited options. This advancement may reshape the competitive landscape and necessitate strategic adjustments in portfolio management and investment decisions.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor further results from the PANOVA-3 trial and subsequent cost-effectiveness analyses that may influence adoption in clinical practice.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.